Article

Applied Clinical Trials

CRF Health’s TrialMax Touch® Selected for Pediatric Rare Disease Phase II Study

CRF Health has been selected by a specialty pharmaceutical company for its latest pediatric rare disease Phase II study. CRF Health's TrialMax Touch® handheld device alone with other solutions will be utilized to collect quality of life readings and alleviate the burden of data entry for caregivers. 

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
Credit: Proxima Studio | stock.adobe.com. While BGM remains the regulatory gold standard, CGM is gaining ground in exploratory endpoints and safety monitoring
August 28th 2025

Beyond the Fingerstick: Navigating CGM and BGM Decisions in GLP-1 Clinical Trials

Karl McEvoy, PhD, and Aubrey Verna
ACT Brief Episode 6: Supreme Court Ruling, VK2735 Obesity Trial, and Padcev-Keytruda Survival Gains
August 28th 2025

ACT Brief Episode 6: Supreme Court Ruling, VK2735 Obesity Trial, and Padcev-Keytruda Survival Gains

Andy Studna, Senior Editor
Image Credit: Adobe Stock Images/Robin
August 28th 2025

Phase III NIMBLE Trial Demonstrates Cemdisiran Efficacy in Generalized Myasthenia Gravis

Andy Studna, Senior Editor
ACT Brief Episode 5: How Digital Twins and AI Are Reshaping Clinical Trials
August 28th 2025

ACT Brief Episode 5: How Digital Twins and AI Are Reshaping Clinical Trials

Andy Studna, Senior Editor
Credit: Dzmitry | stock.adobe.com. SMA can range from severe cases that develop during infancy to milder forms of the disease that manifest later in life.
August 28th 2025

Evrysdi Helps Presymptomatic Infants with Spinal Muscular Atrophy Sit, Stand, and Walk in Phase II Trial

Davy James
Phase I/II RAINFOL-01 Trial Results Lead to FDA Breakthrough Designation for Genmab’s Rina-S for Advanced Endometrial Cancer
August 28th 2025

Phase I/II RAINFOL-01 Trial Results Lead to FDA Breakthrough Designation for Genmab’s Rina-S for Advanced Endometrial Cancer

Don Tracy, Associate Editor
© 2025 MJH Life Sciences

All rights reserved.